• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Proof of Concept of a Personalized Genetic Risk Tool to Promote Smoking Cessation: High Acceptability and Reduced Cigarette Smoking.促进戒烟的个性化遗传风险工具的概念验证:高接受度和减少吸烟。
Cancer Prev Res (Phila). 2021 Feb;14(2):253-262. doi: 10.1158/1940-6207.CAPR-20-0328. Epub 2020 Sep 21.
2
In-vivo design feedback and perceived utility of a genetically-informed smoking risk tool among current smokers in the community.社区中当前吸烟者对基于遗传信息的吸烟风险工具的体内设计反馈和感知效用。
BMC Med Genomics. 2021 May 26;14(1):139. doi: 10.1186/s12920-021-00976-1.
3
Effectiveness of a Brief Self-determination Theory-Based Smoking Cessation Intervention for Smokers at Emergency Departments in Hong Kong: A Randomized Clinical Trial.基于简短自我决定理论的戒烟干预措施对香港急诊科吸烟者的有效性:一项随机临床试验。
JAMA Intern Med. 2020 Feb 1;180(2):206-214. doi: 10.1001/jamainternmed.2019.5176.
4
Varenicline versus placebo for waterpipe smoking cessation: a double-blind randomized controlled trial.伐仑克林与安慰剂治疗水烟戒烟的双盲随机对照试验。
Addiction. 2018 Dec;113(12):2290-2299. doi: 10.1111/add.14430. Epub 2018 Sep 27.
5
Smoking Cessation in the ITALUNG Lung Cancer Screening: What Does "Teachable Moment" Mean?ITALUNG 肺癌筛查中的戒烟:“可教时刻”意味着什么?
Nicotine Tob Res. 2020 Aug 24;22(9):1484-1491. doi: 10.1093/ntr/ntz148.
6
The Role of Nicotine Dependence in E-Cigarettes' Potential for Smoking Reduction.尼古丁依赖在电子烟减少吸烟潜力中的作用。
Nicotine Tob Res. 2018 Sep 4;20(10):1272-1277. doi: 10.1093/ntr/ntx160.
7
Comparing the Efficacy of an Identical, Tailored Smoking Cessation Intervention Delivered by Mobile Text Messaging Versus Email: Randomized Controlled Trial.比较通过手机短信和电子邮件提供的相同定制戒烟干预措施的效果:随机对照试验。
JMIR Mhealth Uhealth. 2019 Sep 27;7(9):e12137. doi: 10.2196/12137.
8
A pilot randomised trial to assess the methods and procedures for evaluating the clinical effectiveness and cost-effectiveness of Exercise Assisted Reduction then Stop (EARS) among disadvantaged smokers.一项评估运动辅助戒烟(EARS)对弱势吸烟者的临床效果和成本效益的方法和程序的初步随机试验。
Health Technol Assess. 2014 Jan;18(4):1-324. doi: 10.3310/hta18040.
9
A Qualitative Examination of Stay Quit Coach, A Mobile Application for Veteran Smokers With Posttraumatic Stress Disorder.定性研究退伍老兵烟民(患有创伤后应激障碍)使用戒烟教练手机应用软件的情况
Nicotine Tob Res. 2020 Apr 17;22(4):560-569. doi: 10.1093/ntr/ntz037.
10
Individual Predictors of Response to A Behavioral Activation-Based Digital Smoking Cessation Intervention: A Machine Learning Approach.基于行为激活的数字戒烟干预措施反应的个体预测因素:一种机器学习方法。
Subst Use Misuse. 2024;59(11):1620-1628. doi: 10.1080/10826084.2024.2369155. Epub 2024 Jun 19.

引用本文的文献

1
Ancestry-Specific Hypothetical Genetic Feedback About Lung Cancer Risk in African American Individuals Who Smoke: Cognitive, Emotional, and Motivational Effects on Cessation.针对非裔美国吸烟者肺癌风险的特定血统假设性基因反馈:对戒烟的认知、情感和动机影响
Behav Sci (Basel). 2025 Jul 19;15(7):980. doi: 10.3390/bs15070980.
2
Genomic insights for personalised care in lung cancer and smoking cessation: motivating at-risk individuals toward evidence-based health practices.肺癌个性化护理与戒烟的基因组学见解:激励高危个体采取循证健康行为。
EBioMedicine. 2024 Dec;110:105441. doi: 10.1016/j.ebiom.2024.105441. Epub 2024 Nov 8.
3
Considerations for the application of polygenic scores to clinical care of individuals with substance use disorders.考虑将多基因评分应用于物质使用障碍个体的临床护理。
J Clin Invest. 2024 Oct 15;134(20):e172882. doi: 10.1172/JCI172882.
4
Genomic medicine to reduce tobacco and related disorders: Translation to precision prevention and treatment.基因组医学用于减少烟草及相关疾病:向精准预防与治疗的转化。
Addict Neurosci. 2023 Sep;7. doi: 10.1016/j.addicn.2023.100083. Epub 2023 Apr 1.
5
A scoping review of smoking cessation pharmacogenetic studies to advance future research across racial, ethnic, and ancestral populations.一项关于戒烟药物遗传学研究的范围综述,以推动未来跨种族、族裔和祖先群体的研究。
Front Genet. 2023 Jun 8;14:1103966. doi: 10.3389/fgene.2023.1103966. eCollection 2023.
6
Can Treatment Support Mitigate Nicotine Metabolism-Based Disparities in Smoking Abstinence? Secondary Analysis of the Helping HAND 4 Trial.治疗支持能否减轻基于尼古丁代谢的戒烟差异?HAND 4 试验的二次分析。
Nicotine Tob Res. 2023 Aug 19;25(9):1575-1584. doi: 10.1093/ntr/ntad079.
7
Global burden of cancers attributable to tobacco smoking, 1990-2019: an ecological study.1990 - 2019年吸烟导致的全球癌症负担:一项生态学研究
EPMA J. 2022 Dec 15;14(1):167-182. doi: 10.1007/s13167-022-00308-y. eCollection 2023 Mar.
8
Are polygenic risk scores ready for the cancer clinic?-a perspective.多基因风险评分是否已准备好应用于癌症临床实践?——一种观点。
Transl Lung Cancer Res. 2022 May;11(5):910-919. doi: 10.21037/tlcr-21-698.
9
In-vivo design feedback and perceived utility of a genetically-informed smoking risk tool among current smokers in the community.社区中当前吸烟者对基于遗传信息的吸烟风险工具的体内设计反馈和感知效用。
BMC Med Genomics. 2021 May 26;14(1):139. doi: 10.1186/s12920-021-00976-1.

本文引用的文献

1
Participatory Design of a Personalized Genetic Risk Tool to Promote Behavioral Health.用于促进行为健康的个性化遗传风险工具的参与式设计。
Cancer Prev Res (Phila). 2020 Jul;13(7):583-592. doi: 10.1158/1940-6207.CAPR-20-0029. Epub 2020 Mar 24.
2
Attitudes toward Precision Treatment of Smoking in the Southern Community Cohort Study.对南方社区队列研究中吸烟精准治疗态度的研究。
Cancer Epidemiol Biomarkers Prev. 2019 Aug;28(8):1345-1352. doi: 10.1158/1055-9965.EPI-19-0179. Epub 2019 Jun 3.
3
2018 Langley Award for Basic Research on Nicotine and Tobacco: Bringing Precision Medicine to Smoking Cessation.2018 年兰利奖基础尼古丁与烟草研究奖:将精准医学应用于戒烟。
Nicotine Tob Res. 2020 Feb 6;22(2):147-151. doi: 10.1093/ntr/ntz036.
4
Optimal Integration of Behavioral Medicine into Clinical Genetics and Genomics.最佳整合行为医学于临床遗传学与基因组学。
Am J Hum Genet. 2019 Feb 7;104(2):193-196. doi: 10.1016/j.ajhg.2019.01.011.
5
Most Current Smokers Desire Genetic Susceptibility Testing and Genetically-Efficacious Medication.大多数当前吸烟者希望进行遗传易感性测试和基因有效药物治疗。
J Neuroimmune Pharmacol. 2018 Dec;13(4):430-437. doi: 10.1007/s11481-018-9818-1. Epub 2018 Oct 29.
6
Behavioral impact of return of genetic test results for complex disease: Systematic review and meta-analysis.复杂疾病遗传检测结果回报的行为影响:系统评价和荟萃分析。
Health Psychol. 2018 Dec;37(12):1134-1144. doi: 10.1037/hea0000683. Epub 2018 Oct 11.
7
The Clinical Sequencing Evidence-Generating Research Consortium: Integrating Genomic Sequencing in Diverse and Medically Underserved Populations.临床测序证据生成研究联盟:在不同和医疗资源不足的人群中整合基因组测序。
Am J Hum Genet. 2018 Sep 6;103(3):319-327. doi: 10.1016/j.ajhg.2018.08.007.
8
Toward the implementation of genomic applications for smoking cessation and smoking-related diseases.朝着实现基因组应用以戒烟和与吸烟相关的疾病的方向努力。
Transl Behav Med. 2018 Jan 29;8(1):7-17. doi: 10.1093/tbm/ibx060.
9
Developing a common framework for evaluating the implementation of genomic medicine interventions in clinical care: the IGNITE Network's Common Measures Working Group.制定一个评估基因组医学干预措施在临床护理中实施情况的通用框架:IGNITE 网络的通用措施工作组。
Genet Med. 2018 Jun;20(6):655-663. doi: 10.1038/gim.2017.144. Epub 2017 Sep 14.
10
Internet-based interventions for smoking cessation.基于互联网的戒烟干预措施。
Cochrane Database Syst Rev. 2017 Sep 4;9(9):CD007078. doi: 10.1002/14651858.CD007078.pub5.

促进戒烟的个性化遗传风险工具的概念验证:高接受度和减少吸烟。

Proof of Concept of a Personalized Genetic Risk Tool to Promote Smoking Cessation: High Acceptability and Reduced Cigarette Smoking.

机构信息

Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri.

Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

出版信息

Cancer Prev Res (Phila). 2021 Feb;14(2):253-262. doi: 10.1158/1940-6207.CAPR-20-0328. Epub 2020 Sep 21.

DOI:10.1158/1940-6207.CAPR-20-0328
PMID:32958583
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7981287/
Abstract

Relatively little is known about the possible effects of personalized genetic risk information on smoking, the leading preventable cause of morbidity and mortality. We examined the acceptability and potential behavior change associated with a personalized genetically informed risk tool () among current smokers. Current smokers ( = 108) were enrolled in a pre-post study with three visits. At visit 1, participants completed a baseline assessment and genetic testing via 23andMe. Participants' raw genetic data ( variants) and smoking heaviness were used to create a tailored tool that communicated personalized risks of smoking-related diseases and evidence-based recommendations to promote cessation. Participants received their personalized intervention at visit 2, approximately 6 weeks later. Visit 3 involved a telephone-based follow-up assessment 30 days after intervention. Of enrolled participants, 83% were retained across the three visits. Immediately following intervention, acceptability of was high (M = 4.4; SD = 0.6 on scale of 1 to 5); at 30-day follow-up, 89% of participants demonstrated accurate recall of key intervention messages. In the full analysis set of this single-arm trial, cigarettes smoked per day decreased from intervention to 30-day follow-up [11.3 vs. 9.8; difference = 1.5; 95% confidence interval (0.6-2.4); = 0.001]. A personalized genetically informed risk tool was found to be highly acceptable and associated with a reduction in smoking, although the absence of a control group must be addressed in future research. This study demonstrates proof of concept for translating key basic science findings into a genetically informed risk tool that was used to promote progress toward smoking cessation. This study demonstrates that personal genetic information can be incorporated into a risk feedback tool that was highly acceptable to current smokers and associated with reductions in smoking. These findings may pave the way for effectiveness and implementation research on genetically-informed behavior change interventions to enhance cancer prevention efforts.

摘要

关于个性化遗传风险信息对吸烟的可能影响,人们知之甚少,而吸烟是发病率和死亡率的首要可预防原因。我们研究了在当前吸烟者中,一种个性化遗传风险工具的可接受性和潜在行为改变。当前吸烟者(n=108)参与了一项有三个访问的前后研究。在第一次访问中,参与者完成了基线评估和 23andMe 的基因测试。参与者的原始基因数据(变体)和吸烟量用于创建一个定制的工具,该工具传达与吸烟相关疾病的个性化风险和促进戒烟的循证建议。大约 6 周后,参与者在第二次访问中收到了他们的个性化干预。第三次访问包括干预后 30 天的电话随访评估。在登记的参与者中,83%在三次访问中都得到了保留。干预后立即,对 的可接受性很高(量表 1 到 5,平均值为 4.4;标准差为 0.6);在 30 天随访时,89%的参与者准确回忆起了关键的干预信息。在这项单臂试验的全分析集中,每天吸烟的数量从干预到 30 天随访减少了[11.3 比 9.8;差异=1.5;95%置信区间(0.6-2.4);P=0.001]。研究发现,一种个性化遗传风险工具非常容易被接受,并与吸烟量减少相关,尽管未来的研究必须解决没有对照组的问题。这项研究证明了将关键基础科学发现转化为促进戒烟的遗传风险工具的概念验证。这项研究表明,个人遗传信息可以被纳入一个高度被当前吸烟者接受的风险反馈工具,与吸烟减少有关。这些发现可能为在遗传信息干预方面开展有效性和实施研究铺平道路,以加强癌症预防工作。